Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO, Cornforth AN, Depriest C, McClay EF, Amatruda TT, de Leon C, Ellis RE, Mayorga C, Carbonell D, Cubellis JM. Dillman RO, et al. Among authors: de leon c. J Immunother. 2012 Oct;35(8):641-9. doi: 10.1097/CJI.0b013e31826f79c8. J Immunother. 2012. PMID: 22996370 Clinical Trial.
Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K. Dillman RO, et al. Among authors: de leon c. Cancer Biother Radiopharm. 2009 Jun;24(3):311-9. doi: 10.1089/cbr.2008.0599. Cancer Biother Radiopharm. 2009. PMID: 19538053
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C. Dillman RO, et al. Among authors: de leon c. Cancer Biother Radiopharm. 2015 Jun;30(5):187-94. doi: 10.1089/cbr.2015.1843. Cancer Biother Radiopharm. 2015. PMID: 26083950 Free PMC article. Clinical Trial.
Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
Dillman RO, Beutel LD, Barth NM, de Leon C, O'Connor AA, DePriest C, Nayak SK. Dillman RO, et al. Among authors: de leon c. Cancer Biother Radiopharm. 2002 Feb;17(1):51-66. doi: 10.1089/10849780252824073. Cancer Biother Radiopharm. 2002. PMID: 11915174 Clinical Trial.
Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO, Wiemann M, Nayak SK, DeLeon C, Hood K, DePriest C. Dillman RO, et al. J Immunother. 2003 Jul-Aug;26(4):367-73. doi: 10.1097/00002371-200307000-00009. J Immunother. 2003. PMID: 12843799 Clinical Trial.
163 results